Transfusional iron overload and its consequences are increasingly recognized in MDS.
Evidence suggests iron overload affects clonal evolution and progression to AML.
Pre-existing iron overload can also influence HSCT outcomes.
Appropriate monitoring of body iron levels can help reduce iron-related toxicity.
Prevention of organ and bone marrow damage may improve clinical outcomes.